AD_____

MIPR NO: 95MM5621

TITLE: Stress and Immune Function: Regulation of Adrenergic Receptors in Human B Lymphocytes

PRINCIPAL INVESTIGATOR(S): George C. Tsokos, Ph.D.

CONTRACTING ORGANIZATION: Walter Reed Army Medical Center
Washington, DC 20307-5001

REPORT DATE: May 1996

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Frederick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

19960909 167

DTIC QUALITY INSPECTED 1

DISCLAIMER NOTICE



THIS DOCUMENT IS BEST QUALITY AVAILABLE. THE COPY FURNISHED TO DTIC CONTAINED A SIGNIFICANT NUMBER OF COLOR PAGES WHICH DO NOT REPRODUCE LEGIBLY ON BLACK AND WHITE MICROFICHE.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE	3. REPORT TYPE AND DATES COVERED
	May 1996	Final (1 May 95 - 30 Apr 96)

4. TITLE AND SUBTITLE
Stress and Immune Function: Regulation of Adrenergic Receptors in Human B Lymphocytes

5. FUNDING NUMBERS
95MM5621

6. AUTHOR(S)
George C. Tsokos, Ph.D.

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)
Walter Reed Army Medical Center
Washington, DC 20307-5001

8. PERFORMING ORGANIZATION REPORT NUMBER

9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)
U.S. Army Medical Research and Materiel Command
Fort Detrick
Frederick, Maryland 21702-5012

10. SPONSORING/MONITORING AGENCY REPORT NUMBER

11. SUPPLEMENTARY NOTES

12a. DISTRIBUTION/AVAILABILITY STATEMENT
Approved for public release; distribution unlimited

12b. DISTRIBUTION CODE

13. ABSTRACT *(Maximum 200 words)*

During the previous year we have investigated the effects of interleukin-1 (IL-1) and interleukin-6 (IL-6) on the density and function of beta to 2 adrenergic receptor (AR) protein and steady state mRNA levels in human lymphoblastoid cell lines. We established a DNA-excess solution hybridization assay using M13-beta-2AR (111) template DNA. This assay helped us detect small changes in the message for beta-2AR. We treated Epstein-Barr (EB) virus transformed human B lymphoblastoid cells and an antibody-secreting lymphoblastoid cell line (IM9) with IL-1 and IL-6. Treatment of the cells with the cytokines caused a marked decrease in the density of beta-2AR but failed to change the affinity of the receptors for the ligand. In contrast, treatment of B cells with both cytokines resulted in increase in the beta-2AR message in both cell lines. To investigate the discrepancy between the effect of lymphokines on receptor protein and its message, we conducted a transcription experiment by using nuclear run-off assays in which we demonstrated that lymphokines increase the stability of the mRNA for beta-2AR. These results demonstrate that lymphokines may alter the expression of stress receptors in human lymphocytes. We conclude that stress receptors interact at the molecular level with elements of the immune system.

14. SUBJECT TERMS	15. NUMBER OF PAGES
Lymphokines; immune response: adrenergic receptors; immunology; stress response	13
	16. PRICE CODE

17. SECURITY CLASSIFICATION OF REPORT	18. SECURITY CLASSIFICATION OF THIS PAGE	19. SECURITY CLASSIFICATION OF ABSTRACT	20. LIMITATION OF ABSTRACT
Unclassified	Unclassified	Unclassified	Unlimited

GENERAL INSTRUCTIONS FOR COMPLETING SF 298

The Report Documentation Page (RDP) is used in announcing and cataloging reports. It is important that this information be consistent with the rest of the report, particularly the cover and title page. Instructions for filling in each block of the form follow. It is important to *stay within the lines* to meet ***optical scanning requirements***.

Block 1. Agency Use Only *(Leave blank)*.

Block 2. Report Date. Full publication date including day, month, and year, if available (e.g. 1 Jan 88). Must cite at least the year.

Block 3. Type of Report and Dates Covered. State whether report is interim, final, etc. If applicable, enter inclusive report dates (e.g. 10 Jun 87 - 30 Jun 88).

Block 4. Title and Subtitle. A title is taken from the part of the report that provides the most meaningful and complete information. When a report is prepared in more than one volume, repeat the primary title, add volume number, and include subtitle for the specific volume. On classified documents enter the title classification in parentheses.

Block 5. Funding Numbers. To include contract and grant numbers; may include program element number(s), project number(s), task number(s), and work unit number(s). Use the following labels:

C	- Contract	**PR**	- Project
G	- Grant	**TA**	- Task
PE	- Program Element	**WU**	- Work Unit Accession No.

Block 6. Author(s). Name(s) of person(s) responsible for writing the report, performing the research, or credited with the content of the report. If editor or compiler, this should follow the name(s).

Block 7. Performing Organization Name(s) and Address(es). Self-explanatory.

Block 8. Performing Organization Report Number. Enter the unique alphanumeric report number(s) assigned by the organization performing the report.

Block 9. Sponsoring/Monitoring Agency Name(s) and Address(es). Self-explanatory.

Block 10. Sponsoring/Monitoring Agency Report Number. *(If known)*

Block 11. Supplementary Notes. Enter information not included elsewhere such as: Prepared in cooperation with...; Trans. of...; To be published in.... When a report is revised, include a statement whether the new report supersedes or supplements the older report.

Block 12a. Distribution/Availability Statement. Denotes public availability or limitations. Cite any availability to the public. Enter additional limitations or special markings in all capitals (e.g. NOFORN, REL, ITAR).

DOD - See DoDD 5230.24, "Distribution Statements on Technical Documents."
DOE - See authorities.
NASA - See Handbook NHB 2200.2.
NTIS - Leave blank.

Block 12b. Distribution Code.

DOD - Leave blank.
DOE - Enter DOE distribution categories from the Standard Distribution for Unclassified Scientific and Technical Reports.
NASA - Leave blank.
NTIS - Leave blank.

Block 13. Abstract. Include a brief *(Maximum 200 words)* factual summary of the most significant information contained in the report.

Block 14. Subject Terms. Keywords or phrases identifying major subjects in the report.

Block 15. Number of Pages. Enter the total number of pages.

Block 16. Price Code. Enter appropriate price code *(NTIS only)*.

Blocks 17. - 19. Security Classifications. Self-explanatory. Enter U.S. Security Classification in accordance with U.S. Security Regulations (i.e., UNCLASSIFIED). If form contains classified information, stamp classification on the top and bottom of the page.

Block 20. Limitation of Abstract. This block must be completed to assign a limitation to the abstract. Enter either UL (unlimited) or SAR (same as report). An entry in this block is necessary if the abstract is to be limited. If blank, the abstract is assumed to be unlimited.

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the US Army.

N/A Where copyrighted material is quoted, permission has been obtained to use such material.

N/A Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

N/A Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

N/A In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

N/A For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

N/A In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

N/A In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

N/A In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

O Mak 5/8/96

PI - Signature Date

Table of Contents:

INTRODUCTION

The presence of ß2-adrenergic receptors (ß2AR) on the surface of lymphocytes makes them susceptible to sympathetic stimulation. ß2AR agonist stimulation inhibits lymphocyte proliferation, mitogen induced secretion of IL-2 and expression of IL-2 receptors. The density of lymphocyte ß2AR is influenced by a variety of physiological and pathophysiological conditions, including stress. There is evidence that shock-induced immune suppression is at least partially mediated by adrenal hormones and peripheral ßAR. Interleukins alter the ßAR responsiveness in lymphocytes as well as in pituitary cells suggesting that they may have an important functional role in the integrated regulatory response to environmental stimuli.

In the present study, we have investigated the effects of IL-1 and IL-6 on the density and function of ß2AR protein and steady state mRNA levels in human lymphoblastoid cell lines.

METHODS

Cells and treatment. Epstein-Barr virus (EBV)-transformed normal human B-lymphocytes and an antibody secreting lymphoblastoid cell line (IM-9, ATCC) were treated with IL-1a and IL-6 (30 IU/ml) for 24 hrs, unless otherwise indicated.

Receptor binding assay. The affinity and density of ßAR were assessed by receptor binding assay using ^{125}I-iodocyanopindolol as radioligand. The saturation isoterms were evaluated using the LIGAND computer program.

DNA-excess solution hybridization assay. In order to selectively measure the amount of the ß2AR mRNA in total RNA preparations from lymphocytes, a 111 nucleotide long single stranded cDNA probe specific for the mRNA of the human $ß_2$AR was synthesized and used in a DNA-excess solution hybridization assay as previously described (Szentendrei et al., J. Cell Physiol. 152:478, 1992). The assay is sensitive enough to reproducibly detect minor changes in the steady state level of the ß2AR mRNA, which proved to be 0.2-0.3 amol mRNA/mg total RNA in the lymphocyte cell lines studied. The sensitivity and linearity of the assay is illustrated on the standard curve which is used to calculate the unknown amount of mRNA (Fig. 1.)

cAMP accumulation. The cAMP accumulation was assayed in intact lymphocytes following 10 min stimulation with 10 µM isoproterenol using a commercial cAMP assay kit (Amersham).

Figure 1. Standard curve for DNA-excess solution hybridization assay, using M13ß$_2$AR(111) template DNA.



Figure 2. Saturation isoterms to asses the ßAR density and affinity in EBV-transformed human lymphocytes (Scatchard plot).
Both cytokines *decrease* the number of ß-adrenergic receptors without significantly changing the affinity. The corresponding B_{max} values: control, 12.6 fmol/mg protein; IL-1, 7.4 fmol/mg protein (59 % of control); IL-6, 9.3 fmol/mg protein (74 % of control). The affinity of the receptor is 60 pmol.



Figure 3. Saturation isoterms to asses the ßAR density and affinity in IM-9 lymphocytes (Scatchard plot).
Both cytokines *decrease* the number of ß-adrenergic receptors without significantly changing the affinity. The corresponding B_{max} values: control, 19.5 fmol/mg protein; IL-1, 15.3 fmol/mg protein (78 % of control); IL-6, 17.2 fmol/mg protein (88 % of control). The affinity of the receptor is 177 pmol.



Figure 4. Isoproterenol-stimulated cAMP accumulation in EBV transformed lymphocytes after 24 hr IL-1 treatment (30 U/ml).
The IL-1 treated cells do not respond to the ß-adrenergic agonist stimulation.



Figure 5. Steady state ß2AR mRNA concentrations in EBV transformed lymphocytes and in IM-9 lymphocytes following 24 hr IL-1 and IL-6 treatment (30 U/ml). Both cytokines *increase* the ß2AR message in both cell lines, but the effect is more pronounced in the EBV transformed cell line.



Figure 6. Time course of IL-1 and IL-6 effect on ß2AR mRNA levels in EBV-transformed and IM-9 cell lines.
That the cytokines had a maximum effect at 8 hr in EBV-transformed lymphocytes, and at 2 hr in IM-9 lymphocytes, and the effect on EBV cells was much more profound than that on the IM-9 cells.



Conclusions:

During the last year we succesfully completed the work proposed for the first phase. The results are being prepared for publication. Our results have clearly shown that the beta-2 adrenergic receptors (AR) are subject to regulation by elements of the immune system such as lymphokines. Therefore a clear link between the stress responisve elements and the immune system have been proven. These results indicate that stress response can be modulated by immune parameters.

We would like you to consider continuation of funding of this promising project so we may continue with the remaining phases of the project.

POC is:

George C. Tsokos, LTC, MC

tel (301) 782 9240